Real-world Outcomes of Hepatitis C Treatment during the Interferon-free Era at an Urban Safety-net Hospital
| Autor: | C. Robert Horsburgh, Sabrina A. Assoumou, Benjamin P. Linas, Kraig L. Young, Wei Huang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male medicine.medical_specialty Sofosbuvir Adolescent Sustained Virologic Response Hepatitis C virus Hepacivirus medicine.disease_cause Antiviral Agents Article 03 medical and health sciences Young Adult 0302 clinical medicine Hospitals Urban Internal medicine Health care medicine Humans 030212 general & internal medicine Medical prescription Aged Retrospective Studies Aged 80 and over business.industry Public Health Environmental and Occupational Health Retrospective cohort study Hepatitis C Middle Aged medicine.disease Clinical trial Treatment Outcome Cohort Physical therapy RNA Viral 030211 gastroenterology & hepatology Female Interferons business Safety-net Providers medicine.drug |
| Popis: | BACKGROUND Little is known about real-world outcomes for new interferon-free treatment for hepatitis C virus (HCV) among underserved and diverse communities. OBJECTIVE To identify predictors of treatment prescription and evaluate outcomes as measured by sustained virologic response (SVR) with HCV RNA testing three months after therapy completion. DESIGN Retrospective cohort at a safety-net health care system. PARTICIPANTS Patients with (1) at least one clinical visit between December 6, 2013, and December 31st 2014; and (2) at least three months follow-up. KEY RESULTS Predominantly non-White cohort (61%). Of 1,284 HCV-infected patients 121 prescribed sofosbuvir-based therapy. Severe liver fibrosis (OR 1.66, 95% CI 1.05, 2.64) independently associated with treatment prescription. In those with evaluable HCV RNA, SVR was 99%. CONCLUSION Cure rates similar to clinical trial data can be achieved in diverse underserved communities. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|